Enliven Therapeutics (ELVN) holds an average "Moderate Buy" analyst rating with a $41.20 price target and recently surpassed Q3 EPS estimates by $0.11. Despite this positive earnings beat and analyst sentiment, the company has seen significant insider selling, with executives offloading over $2 million in shares in the last 90 days. Conversely, major institutional investors, including Goldman Sachs and Russell Investments, have substantially increased their stakes, pushing institutional ownership to 95.08% and highlighting a notable divergence in investor conviction.
Enliven Therapeutics (ELVN) holds an average "Moderate Buy" rating with a $41.20 price target, reflecting analyst optimism despite a recent "sell" rating from Weiss Ratings. The company recently surpassed Q3 EPS estimates by $0.11, reporting ($0.32) against a ($0.43) consensus, which contributed to an 8.9% stock increase. A notable divergence in investor conviction is apparent. Insiders, including the CFO, have sold 99,984 shares valued at over $2 million in the last 90 days, representing significant ownership decreases. This insider selling, even with 25.90% insider ownership remaining, could signal caution. Conversely, institutional investors have aggressively increased their stakes, with total institutional ownership reaching 95.08%. Firms like Goldman Sachs and Russell Investments significantly boosted their positions in Q1, indicating strong institutional confidence in ELVN's long-term potential as a clinical-stage biopharmaceutical company with lead candidates in Phase 1 trials. This mixed signal environment, combining positive earnings and institutional accumulation with insider selling, creates a complex outlook for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
